Supplemental oxygen reverses hypoxia-induced smooth muscle cell proliferation by modulating HIF-alpha and VEGF levels in a rabbit arteriovenous fistula model

Annals of Vascular Surgery

Volumn 28, Issue 3, 2014, Pages 725-736

  Wan, Jing ^b   Lata, Charu ^a   Santilli, Ashley ^a   Green, Derrick ^a   Roy, Sabita ^a   Santilli, Steven ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 3; OXYGEN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; CYTOKINE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD SAMPLING; BRDU ASSAY; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HYPEROXIA; MALE; NONHUMAN; OXYGEN THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT MODEL; REAL TIME POLYMERASE CHAIN REACTION; SHAM PROCEDURE; SKIN INCISION; SMOOTH MUSCLE FIBER; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMAL; ANOXIA; ARTERIOVENOUS SHUNT; CELL MOTION; HYPERPLASIA; ILIAC ARTERY; ILIAC VEIN; METABOLISM; NEOINTIMA; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; RABBIT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; SURGERY; TIME FACTOR; VASCULAR SMOOTH MUSCLE; WOUND HEALING;

ANIMALS; ANOXIA; ARTERIOVENOUS SHUNT, SURGICAL; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; HYPERPLASIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ILIAC ARTERY; ILIAC VEIN; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 3; MODELS, ANIMAL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; OXYGEN INHALATION THERAPY; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS C-AKT; RABBITS; SIGNAL TRANSDUCTION; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; WOUND HEALING;

EID: 84896932948     PISSN: 08905096     EISSN: 16155947     Source Type: Journal    
DOI: 10.1016/j.avsg.2013.10.007     Document Type: Article

References (29)

1. USRDS. 2010 Annual Data Report. United States Renal Data System. www.usrds.org/adr.htm.
2. Centers for Disease Control and Prevention (CDC). National Chronic Kidney Disease Fact Sheet: General Information and National Estimates on Chronic Kidney Disease in the United States, 2010. Atlanta, GA: U.S. Department of Health and Human Services (HHS), 2010. CDC.
3. Schwab SJ. Vascular access for hemodialysis. Kidney Int 1999;55:2078-90. (Pubitemid 29198003)
4. NKF-K/DOQI clinical practice guidelines for vascular access: update 2000. Am J Kidney Dis 2001;37(Suppl. 1):S137-81.
5. Gibson KD, Gillen DL, Caps MT, et al. Vascular access survival and incidence of revisions: a comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System Dialysis Morbidity and Mortality Study. J Vasc Surg 2001;34:694-700. (Pubitemid 33664921)
6. NKF-K/DOQI clinical practice guidelines for vascular access: update 2006. Am J Kidney Dis 2006;48(Suppl. 1):S176-276.
7. Parthasarathy S, Santanam N, Ramachandran S, et al. Oxidants and antioxidants in atherogenesis - an appraisal. J Lipid Res 1999;40:2143-57.
8. Davies MG, Hagen PO. Pathobiology of intimal hyperplasia. Br J Surg 1994;81:1254-69. (Pubitemid 24275140)
9. Clowes AW, Reidy MA. Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia - a review. J Vasc Surg 1991;13:885-91.
10. Davies MG, Dalen H, Austerheim AM, et al. Suppression of intimal hyperplasia in experimental vein grafts by oral 1-arginine supplementation and single ex vivo immersion in deferoxamine manganese. J Vasc Surg 1996;23:410-20. (Pubitemid 26081280)
11. Chen C, Lumsden AB, Hanson SR. Local infusion of heparin reduces anastomotic neointimal hyperplasia in aortoiliac expanded polytetrafluoroethylene bypass grafts in baboons. J Vasc Surg 2000;31:354-63. (Pubitemid 30100044)
12. Kibbe MR, Nie S, Yoneyama T, et al. Optimization of ex vivo inducible nitric oxide synthase gene transfer to vein grafts. Surgery 1999;126:323-9. (Pubitemid 29382798)
13. Lee ES, Bauer GE, Caldwell MP, et al. Association of artery wall hypoxia and cellular proliferation at a vascular anastomosis. J Surg Res 2000;91:32-7. (Pubitemid 30340892)
14. Lee ES, Caldwell MP, Tretinyak AS, et al. Supplemental oxygen controls cellular proliferation and anastomotic intimal hyperplasia at a vascular graft-to-artery anastomosis in the rabbit. J Vasc Surg 2001;33:608-13. (Pubitemid 32215613)
15. Osada-Oka M, Ikeda T, Imaoka S, et al. VEGF-enhanced proliferation under hypoxia by an autocrine mechanism in human vascular smooth muscle cells. J Atheroscler Thromb 2008;15:26-33.
16. Lauzier MC, Robitaille GA, Chan DA, et al. (2R)-[(4-bip henylylsulfonyl)amino]-N-hydroxy-3-phenylpropionamide (BiPS), a matrix metalloprotease inhibitor, is a novel and potent activator of hypoxia-inducible factors. Mol Pharmacol 2008;74:282-8. (Pubitemid 351872179)
17. Karamysheva AF. Mechanisms of Angiogenesis. Biochemistry 2008;73:935-48.
18. Li WW, Talcott KE, Zhai AW, et al. The role of therapeutic angiogenesis in tissue repair and regeneration. Adv Skin Wound Care 2005;18:491-500. quiz 501-2.
19. Roy H, Bhardwaj S, Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett 2006;580:2879-87. (Pubitemid 43729175)
20. Mukherjee S, Tessema M, Wandinger-Ness A. Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function. Circ Res 2006;98:743-56. Review.
21. Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling: in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-71.
22. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): A dual regulator for angiogenesis. Angiogenesis 2006;9:225-30.
23. Banerjee S, Mehta S, Haque I, et al. VEGF-A165 induces human aortic smooth muscle cell migration by activating neuropilin-1-VEGFR1-PI3K axis. Biochemistry 2008;47:3345-51. (Pubitemid 351399223)
24. Adya R, Tan BK, Punn A, et al. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008;78:356-65. (Pubitemid 351556097)
25. Sivanesan S, How TV, Bakran A. Sites of stenosis in AV fistulae for haemodialysis access. Nephrol Dial Transplant 1999;14:118-20. (Pubitemid 29041879)
26. Houck KA, Ferrara N, Winer J, et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991;5:1806-14.
27. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266:11947-54.
28. Kermani P, Leclerc G, Martel R, et al. Effect of ionizing radiation on thymidine uptake, differentiation, and VEGFR2 receptor expression in endothelial cells: the role of VEGF(165). Int J Radiat Oncol Biol Phys 2001;50:213-20.
29. Lang SA, Schachtschneider P, Moser C, et al. Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. Mol Cancer Ther 2008;7:3509-18.